Study public appearance scripts, slides, and post-event documentation for FINRA Series 161 Supervisory Analyst Part I with learning objectives, review controls, and exam traps.
This Series 161 lesson covers public appearance scripts, slides, and post-event documentation within Serve as Liaison Between Research and Other Parties. Read it as a supervisory analyst approval lesson: the exam usually asks whether a research communication or research interaction should be approved, revised, delayed, restricted, escalated, disclosed, or documented.
This section is most likely to test personal-account preclearance, restricted periods, related and household accounts, public appearance disclosures, scripts and slides, issuer factual verification, investment banking contacts, independence barriers, sales and trading coordination, legal or compliance escalation, dissemination approvals, channel controls, release sequencing, selective dissemination, corrections, updates, and redistribution controls. Strong answers start with the supervisory control issue rather than the attractiveness of the research view. A communication can be analytically plausible and still fail because disclosure, timing, restricted-list status, public-appearance controls, dissemination sequencing, or evidence is weak.
Series 161 rewards role discipline. Think like the approving supervisory analyst, not the analyst, salesperson, investment banker, issuer contact, or marketing reviewer.
Identify who is interacting with research and what risk that contact creates. Then decide whether the supervisory analyst should require preclearance, disclosures, a barrier, legal or compliance escalation, controlled release sequencing, or documented correction before the communication proceeds.
Use this sequence when a stem includes several facts:
| Step | Question | Why it matters |
|---|---|---|
| Classify the item | Is this a research report, public appearance, offering communication, liaison contact, correction, or dissemination event? | The classification controls the review path. |
| Identify the restriction | Is there a list status, quiet period, restricted period, conflict, disclosure, or barrier issue? | It determines whether release should pause. |
| Test the content or contact | Is the statement fair, supportable, balanced, and independent? | Approval depends on substance and process. |
| Preserve evidence | What approval record, disclosure support, preclearance, script, slide deck, correction, or release record should exist? | The firm must prove the supervisory path. |
| If the stem includes… | First concern | Stronger answer pattern |
|---|---|---|
| unclear communication category | scope | classify before approving or applying exemptions |
| missing risk, conflict, rating, or relationship detail | disclosure | revise before publication |
| offering period, list status, or distribution context | timing | delay, restrict, or escalate before release |
| issuer, banking, sales, or trading contact | independence | use barriers, compliance review, and documentation |
| uneven release, correction, or update | dissemination | control sequencing and preserve redistribution evidence |
Before leaving this section, make sure you can address these points: